- Home
- PBYI vs GBLI Comparison
PBYI vs GBLI Comparison
Compare PBYI & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBYI | GBLI |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.9M | 395.4M |
| IPO Year | 2011 | 2010 |
Fundamental Metrics
Financial Performance| Metric | PBYI | GBLI |
|---|---|---|
| Price | $7.57 | $28.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 257.8K | 2.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 5.03% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.61 | ★ 1.75 |
| Revenue | $27,685,000.00 | ★ $450,098,000.00 |
| Revenue This Year | N/A | $14.23 |
| Revenue Next Year | N/A | $9.68 |
| P/E Ratio | ★ $12.41 | $15.90 |
| Revenue Growth | N/A | ★ 2.02 |
| 52 Week Low | $2.75 | $25.88 |
| 52 Week High | $7.90 | $34.00 |
Technical Indicators
Market Signals| Indicator | PBYI | GBLI |
|---|---|---|
| Relative Strength Index (RSI) | 67.52 | 50.69 |
| Support Level | $5.75 | $27.55 |
| Resistance Level | N/A | $28.81 |
| Average True Range (ATR) | 0.33 | 0.28 |
| MACD | 0.14 | 0.05 |
| Stochastic Oscillator | 82.18 | 55.50 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.